In last trading session, Carisma Therapeutics Inc (NASDAQ:CARM) saw 0.3 million shares changing hands with its beta currently measuring 1.61. Company’s recent per share price level of $0.42 trading at -$0.02 or -5.35% at ring of the bell on the day assigns it a market valuation of $17.44M. That closing price of CARM’s stock is at a discount of -652.38% from its 52-week high price of $3.16 and is indicating a premium of 9.52% from its 52-week low price of $0.38. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.54 million shares which gives us an average trading volume of 208.59K if we extend that period to 3-months.
For Carisma Therapeutics Inc (CARM), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.60. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.19 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Carisma Therapeutics Inc (NASDAQ:CARM) trade information
Upright in the red during last session for losing -5.35%, in the last five days CARM remained trading in the green while hitting it’s week-highest on Wednesday, 12/18/24 when the stock touched $0.42 price level, adding 15.37% to its value on the day. Carisma Therapeutics Inc’s shares saw a change of -85.74% in year-to-date performance and have moved 3.24% in past 5-day. Carisma Therapeutics Inc (NASDAQ:CARM) showed a performance of -51.54% in past 30-days. Number of shares sold short was 0.55 million shares which calculate 2.88 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 6 to the stock, which implies a rise of 93.0% to its current value. Analysts have been projecting 6 as a low price target for the stock while placing it at a high target of 6. It follows that stock’s current price would drop -1328.57% in reaching the projected high whereas dropping to the targeted low would mean a loss of -1328.57% for stock’s current value.
Carisma Therapeutics Inc (CARM) estimates and forecasts
Statistics highlight that Carisma Therapeutics Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -62.69% of value to its shares in past 6 months, showing an annual growth rate of 49.03% while that of industry is 16.40. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 43.48% from the last financial year’s standing.
4 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 5.42M for the same. And 2 analysts are in estimates of company making revenue of 4.69M in the next quarter. Company posted 4.29M and 3.4M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 24.98% during past 5 years.
Carisma Therapeutics Inc (NASDAQ:CARM)’s Major holders
Insiders are in possession of 28.54% of company’s total shares while institution are holding 31.47 percent of that, with stock having share float percentage of 44.03%. Investors also watch the number of corporate investors in a company very closely, which is 31.47% institutions for Carisma Therapeutics Inc that are currently holding shares of the company.
